TuHURA Biosciences Inc (HURA)

TuHURA Biosciences Inc (HURA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $117M; returns 1 day +8.5%, 1 week +23.9%, 1 year -2.2%.

TuHURA Biosciences Inc. (HURA) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies to combat cancer immunotherapy resistance. Their lead candidate, IFx-2.0, is a personalized cancer vaccine in Phase 3 trials, designed to overcome primary resistance to checkpoint inhibitors like Keytruda, particularly in advanced Merkel Cell Carcinoma.

Groups HURA belongs to

• Healthcare
• Biotechnology
• Oncology
• Cancer Therapeutics
• Immunotherapy
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Life Sciences
• Precision Medicine
• Personalized Medicine
• R&D

HURA financial model: income statement, cash flow and balance sheet